Completed
A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LINE THERAPY FOR PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER (The ADJUNCT Study)
2025-521489-80-00· Phase 2· Medica Scientia Innovation Research S.L.· Source
Completed
Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)
NCT05828303· Phase 1· Bristol-Myers Squibb Services Unlimited Company· Source
Completed
A trial to learn how well NMS-01940153E works in combination with atezolizumab and priming administration of decitabine or with atezolizumab alone in patients with hepatocellular carcinoma (HCC) that cannot be removed by surgery and who received prior treatment with other anti-cancer medicines
2024-516737-12-00· Phase 2· Nerviano Medical Sciences S.r.l.· Source
Completed
Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer
2024-512754-16-01· Phase 3· Curium US LLC· Source
Completed
A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1
NCT05870748· Phase 2· Sutro Biopharma Inc.· Source
Active, not recruiting
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT06328738· Phase 1· Enliven Therapeutics· Source
Completed
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
NCT06395753· Phase 2· Debiopharm International SA· Source
Completed
A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.
2023-506881-30-00· Phase 1· H e x a l AG· Source
Active, not recruiting
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067· Phase 3· Erasca, Inc.· Source
Completed
A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
2023-506092-10-00· Phase 2· Ascendis Pharma Oncology Division A/S· Source
Completed
Study to Assess the Safety, Tolerability and Efficacy of Lurbinectedin and Dostarlimab treatment in patients with endometrial cancer after disease progression to a previous treatment with Platinum-based Chemotherapy. LiDer trial
2023-508583-30-00· Phase 1/2· Vall D Hebron Institute Of Oncology· Source
Completed
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
2022-502453-33-00· Phase 2· Genmab A/S· Source
Withdrawn
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
NCT05743270· Phase 2· Replimune, Inc.· Source
Active, not recruiting
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632· Phase 2· Pfizer· Source
Completed
A clinical study of bemcentinib with standard of care chemoimmunotherapy in untreated advanced/metastatic non-small cell lung cancer patients with a mutation in the STK11 gene
NCT05469178· Phase 1/2· Bergenbio ASA· Source
Completed
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT05848011· Phase 2· MacroGenics· Source
Completed
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
NCT05938270· Phase 1· AstraZeneca· Source
Recruiting
A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors
NCT05642780· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.· Source
Terminated
Study of ART0380 in Patients With Biologically Selected Solid Tumors
NCT05798611· Phase 2· Artios Pharma Ltd· Source
Completed
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
2022-502267-37-00· Phase 1/2· K-Group Beta Inc.· Source
Active, not recruiting
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
NCT05908734· Phase 1/2· Janssen Research & Development, LLC· Source
Active, not recruiting
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
NCT05663866· Phase 2· Janssen Research & Development, LLC· Source
Completed
A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK)
NCT05551117· Phase 2· Macrogenics Inc.· Source
Completed
A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
2022-501451-87-00· Phase 1/2· Zhejiang Genfleet Therapeutics Co. Ltd.· Source
Active, not recruiting
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
NCT05650879· Phase 1· Enliven Therapeutics· Source
Terminated
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
NCT05743036· Phase 1· K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc· Source
Completed
A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
2023-504111-33-00· Phase 2· Bristol Myers Squibb International Corporation· Source
Completed
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
NCT05546476· Phase 2· Pfizer· Source
Completed
Phase II trial of Pembrolizumab and Olaparib in homologous-recombination deficient (HRD) advanced colorectal cancer (CRC).
NCT05201612· Phase 2· Grupo Espanol Multidisciplinar En Cancer Digestivo· Source
Completed
Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer
NCT05207709· Phase 3· Solti Group· Source
Completed
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.
NCT05181462· Phase 1/2· Cantargia AB· Source
Completed
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
NCT05117242· Phase 2· Genmab A/S· Source
Completed
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
NCT04987203· Phase 3· AVEO Pharmaceuticals, Inc.· Source
Completed
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
NCT04895722· Phase 2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
NCT04739761· Phase 3· AstraZeneca· Source
Completed
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
NCT04689828· Phase 3· Novartis Pharmaceuticals· Source
Terminated
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
NCT04887831· Phase 2· G1 Therapeutics, Inc.· Source
Completed
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04660344· Phase 3· Hoffmann-La Roche· Source
Terminated
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT03850795· Phase 3· Hinova Pharmaceuticals USA, Inc.· Source
Completed
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
NCT04704219· Phase 2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
NCT04657991· Phase 3· Pfizer· Source
Completed
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
NCT03906071· Phase 3· Mirati Therapeutics Inc.· Source
Completed
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
NCT04338399· Phase 3· Adlai Nortye Biopharma Co., Ltd.· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
NCT04597125· Phase 4· Bayer· Source
Completed
Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients
NCT04300790· Phase 2· MedSIR· Source
Completed
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)
NCT04332744· Phase 2· MedSIR· Source
Completed
Clinical Trial to evaluate the efficacy of immunotherapy in a subset of Hormonal Receptor-positive/HER2-negative advanced breast cancer
patients who have progressed to standard therapy.
2023-508546-17-00· Phase 2· Solti Group· Source
Active, not recruiting
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496· Phase 3· AstraZeneca· Source
Completed
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients
NCT04253561· Phase 1· SOLTI Breast Cancer Research Group· Source
Showing 50 of 62.